Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Futibatinib in Combination With Durvalumab (MEDI4736) Administered to Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer Before Cystectomy

NCT06263153 is registered in ClinicalTrials.gov with Yuanquan Yang as lead sponsor.

NCT NCT06263153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06263153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Futibatinib in Combination With Durvalumab (MEDI4736) Administered to Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer Before Cystectomy
Lead sponsor
Yuanquan Yang
Phase
Phase 2
Overall status
Recruiting
Start date
December 30, 2024
Completion date
July 31, 2027
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, muscle invasive bladder carcinoma, stage ii bladder cancer ajcc v8, stage iiia bladder cancer ajcc v8